YmAbs Therapeutics, Inc. YMAB shares rallied 5.2% in the last trading session to close at $14.91. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 8.9% loss over the past four weeks.The rise in share prices is attributable to investor expectations on the company’s marketed drugs and pipeline development. Earlier this week, Y-mAbs announced that it has submitted a regulatory application in Brazil seeking approval for its neuroblastoma drug Danyelza (naxitamab). The drug was approved by the FDA under accelerated pathway for treating relapsed or refractory high-risk neuroblastoma in individuals aged one year and older in 2020.This company is expected to post quarterly loss of $0.69 per share in its upcoming report, which represents a year-over-year change of -4.6%. Revenues are expected to be $15.43 million, up 72% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For YmAbs Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on YMAB going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>YmAbs Therapeutics, Inc. is part of the Zacks Medical - Biomedical and Genetics industry. Exact Sciences EXAS, another stock in the same industry, closed the last trading session 7.7% higher at $34.44. EXAS has returned -10.2% in the past month.Exact Sciences' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.09. Compared to the company's year-ago EPS, this represents a change of -12.4%. Exact Sciences currently boasts a Zacks Rank of #3 (Hold). FREE Report: The Metaverse is Exploding! Don’t You Want to Cash In? Rising gas prices. The war in Ukraine. America's recession. Inflation. It's no wonder why the metaverse is so popular and growing every day. Becoming Spider Man and fighting Darth Vader is infinitely more appealing than spending over $5 per gallon at the pump. And that appeal is why the metaverse can provide such massive gains for investors. But do you know where to look? Do you know which metaverse stocks to buy and which to avoid? In a new FREE report from Zacks' leading stock specialist, we reveal how you could profit from the internet’s next evolution. Even though the popularity of the metaverse is spreading like wildfire, investors like you can still get in on the ground floor and cash in. Don't miss your chance to get your piece of this innovative $30 trillion opportunity - FREE.>>Yes, I want to know the top metaverse stocks for 2022>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report YmAbs Therapeutics, Inc. (YMAB): Free Stock Analysis Report Exact Sciences Corporation (EXAS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research